Paper Details

  1. Home
  2. Paper Details

Hybrid drug combination: Anti-diabetic treatment of type 2 diabetic Wistar rats with combination of ellagic acid and pioglitazone.

Author: DobleMukesh, NankarRakesh P

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Pioglitazone, a drug for type 2 diabetes, was temporarily withdrawn from the Indian market due to concerns about bladder cancer risk. However, it was reintroduced because its benefits outweighed the risks. Reducing the dose of pioglitazone can minimize these risks.
Paper Details　
Original Abstract of the Article :
Pioglitazone is an effective drug for the treatment of type 2 diabetes. The drug was suspended from Indian market in June 2013 due to the risk of bladder cancer but was reintroduced in July 2013 because its benefits outweighed the risks. The risks associated with pioglitazone can be minimized if its...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.phymed.2017.10.014

データ提供：米国国立医学図書館（NLM）

Hybrid Drug Combinations: A New Approach to Diabetes Treatment

Diabetes is a growing global health concern, and finding effective and safe treatment options is critical. This study, like a camel seeking a refreshing oasis in the arid landscape of diabetes research, explores the potential of a hybrid drug combination for treating type 2 diabetes.

The study investigates the combination of ellagic acid, a natural compound, and pioglitazone, a synthetic drug, in treating type 2 diabetic rats. Pioglitazone is a known effective drug but has been associated with potential risks like bladder cancer. This study explores the possibility of reducing the dose of pioglitazone while enhancing its effectiveness with the addition of ellagic acid.

The research found that the combination of ellagic acid and pioglitazone demonstrated significant anti-diabetic activity in type 2 diabetic rats. The combination effectively lowered blood glucose levels, improved insulin sensitivity, and reduced lipid levels.

A Promising Combination for Diabetes Management

This study suggests that the combination of ellagic acid and pioglitazone could be a promising approach for managing type 2 diabetes. The combination offers the potential to enhance the efficacy of pioglitazone while minimizing the risks associated with higher doses.

Navigating the Complexity of Diabetes Treatment

The study highlights the need for innovative approaches in diabetes management. The research suggests that exploring hybrid drug combinations, combining natural and synthetic compounds, could pave the way for more effective and safer treatment options.

Dr.Camel's Conclusion

This study demonstrates that a hybrid drug combination of ellagic acid and pioglitazone could offer a promising strategy for managing type 2 diabetes. The findings suggest that this combination may provide a more effective and potentially safer alternative to the use of higher doses of pioglitazone alone.

Date :
  1. Date Completed 2018-03-19
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

29103827

DOI: Digital Object Identifier

10.1016/j.phymed.2017.10.014

Related Literature

Article Analysis
・Side Effects of pioglitazone
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.